Cantourage Group SE raises annual forecast for 2024 due to strong year-end business performance
Cantourage Group SE raises annual forecast for 2024 due to strong year-end business performance
Cantourage Group SE (hereinafter “Cantourage,” ISIN: DE000A3DSV01, www.cantourage.com), Europe's leading publicly traded cannabis company, generated monthly sales of approximately EUR 7.2 million in November 2024. This represents a significant increase in revenue of around 30% compared to the previous annual high from the previous month (October 2024: EUR 5.5 million). Cantourage also expects to be able to make optimal use of the continuing strong growth momentum for medical cannabis in December 2024.
Due to the recent strong and profitable sales growth, Cantourage is expected to exceed its annual targets for 2024. The company is therefore raising its full-year forecast for sales and operating profit (EBITDA). Cantourage now expects revenues of between EUR 46 million and EUR 50 million for the full year 2024 (previously: at least EUR 40 million) and EBITDA in the range of EUR 3 million to EUR 4 million (previously: at least EUR 2 million).